ALN-SNCA / Alnylam, Regeneron - LARVOL DELTA

First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • CNS Disorders • Movement Disorders • Parkinson's Disease